PFE Sep 2022 65.000 call
| Previous Close | 0.0300 |
| Open | 0.0200 |
| Bid | 0.0000 |
| Ask | 0.0100 |
| Strike | 65.00 |
| Expire Date | 2022-09-16 |
| Day's Range | 0.0100 - 0.0300 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 11.26k |
- Zacks
Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down
Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.
- Reuters
UPDATE 6-Plaintiff in first Zantac lawsuit set for trial drops case
Tuesday's news came days after shares of GlaxoSmithKline Plc , Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer. The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac. Alexandra Walsh, an attorney for Bayer, said her client could not proceed for "personal health reasons" but had the right to refile his case within a year.
- Reuters
Plaintiff in first Zantac lawsuit set for trial drops case
The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants. Tuesday's news came days after shares of GlaxoSmithKline Plc, Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer. The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac.
